Sat, Jul 12, 2014, 6:00 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

galaberge 97 posts  |  Last Activity: Jul 11, 2014 2:16 PM Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    technically, not good

    by topgunbioinvestor Jul 11, 2014 12:49 PM
    galaberge galaberge Jul 11, 2014 2:16 PM Flag

    postbusters-From where this topgun (?%$&?%) coming from ?? A real #$%$ A small volatility while en route to $30.

    Sentiment: Strong Buy

  • A: "Get rid of the bozos in Wall Street who play to be gurus of the stock markets. Seriously, fire them immediately"

    A joke these few people who can't predict what kind of socks they will wear in 3 days.

    Long and strong HZNP

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 8, 2014 5:57 AM Flag

    Or this link just ggogle "http://finance.yahoo.com/news/synthetic-biologics-reports-ucla-announcement-194500444.html"

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 8, 2014 5:47 AM Flag

    Link to be consulted: Google "cxvascularDOTcom/nn-latest-news/neuro-news---latest-news/phase-ii-study-of-trimesta-for-relapsing-remitting-multiple-sclerosis-yields-positive-efficacy-and-safety-results" for the proof of the press release.

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 7, 2014 10:30 PM Flag

    Trimesta's differentiated mechanism of action, combined with the convenience of once-daily oral dosing, may potentially make it an ideal added therapy to address this underserved $14.1 billion worldwide market," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics."

    So to summarise we have the ACTUAL facts ;

    1- The results after 12 months AND 24 months were 47 % decrease in annualized MS relapse rate (due to the word P-E-R-S-I-S-T-E-D....!!! )

    2-Moreover we had In addition a significant improvement in cognitive function observed at 12 months AND at 24 months as measured by PASAT

    3-Copaxone (from TEVA) alone had ONLY 32% improvement after 24 months

    So if you are 1 of the 260,000 US women and you have to choose between a drug giving almost 50% chances to be cured and the Copaxone (not curing you) with his 32%, WHAT DO YOU CHOOSE ? That's the main question. And the answer is anyone with an ounce of intelligence and judgment will ask for Trimesta. The other 50% not cured will have the same ACTUAL benefits of the ACTUAL treatment with the Copaxone which is the SOC ! Trimesta is made with the exact dosage of the actual treatment with the Copaxone + 8 mg of Estriol.

    I am sure the Trimesta story is just beginning.....for the shareholders and for the sick women. 2/2

    Sentiment: Strong Buy

  • Reply to

    From Jeff Riley's Q-1 Results CC:

    by jrdelane Jul 4, 2014 12:46 AM
    galaberge galaberge Jul 7, 2014 10:09 PM Flag

    If we re-read the press release of the Trimesta's results we see many astonishing things. Let's see what I mean.

    First I will quote and comment :

    "Dr. Voskuhl commented, "Pregnancy is known to be a period of relative protection from MS relapses, and the therapeutic effects of pregnancy hormones, including estriol, include both anti-inflammatory and neuroprotective mechanisms as evidenced in animal models of MS. We are encouraged by the topline results from this first randomized placebo-controlled trial evaluating oral estriol due to the positive impact of adjunctive therapy with estriol on the patients in this study. We look forward to continued clinical evaluation of estriol, which we believe has the potential to slow disease progression and improve quality of life for women with RRMS."
    The Phase II, double-blinded, placebo-controlled trial randomized 158 women with relapsing-remitting MS at 16 sites across the U.S. Among topline results, women receiving Trimesta plus Copaxone demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment as compared to women receiving placebo plus Copaxone. In addition, a significant improvement in cognitive function was observed at 12 months as measured by Paced Auditory Serial Addition Test (PASAT) scores. After 24 months of treatment, the reduction in relapse rate PERSISTED in favor of the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group (32 percent). Both treatment groups exhibited improvement in measures of cognitive function at 24 months. Treatment was safe and well tolerated with no evidence of adverse effects on breast or uterus.
    "The topline data presented today are encouraging for women with MS, including the approximately 260,000 women with MS in the United States. We believe adjunctive therapy with Trimesta has the potential to improve therapeutic outcomes for women currently taking first-line RRMS treatments. 1/2

  • Reply to

    Don't fear the haircuts

    by alien_twin Jul 7, 2014 9:32 AM
    galaberge galaberge Jul 7, 2014 9:37 AM Flag

    If you have nothing intelligent to say shut your mouth and go to another MB where you can buy shares.

    Sentiment: Strong Buy

  • This presentation is a public event and the CEO has to be factual because it's important for all the potential investors and the general audience. Also this presentation is in a written form.

    I quote :

    "3rd Annual Marcum LLP MicroCap Conference
    By Jeffrey Riley, CEO
    May 29, 2014

    Topline results presented at 2014 AAN by Dr. Voskhul demonstrated :

    1-Statiscally significant 47% decrease in annualized MS relapse rate at 12 months with Trimesta+Copaxone compared to placebo+Copaxone (p=0.03/powered for significance level 0.05)

    2-32% decrease in annualized relapse rate at 24 months with Trimesta+Copaxone compared to placebo+Copaxone (p=0.15/powered for significance level 0.10)

    • Per study protocol, investigators anticipated a 29% decrease in relapse rate at both 12 and 24 months

    3-Clinically significant near-normalization of cognitive scores at 12 months of therapy with Trimesta+Copaxone

    • Unique neuroprotective effect of oral estriol highly significant to MS community

    4-Trimesta+Copaxone was generally safe and well tolerated

    Next planned steps for Trimesta for relapsing-remitting MS :

    • Demonstrated therapeutic potential and safety of oral estriol support ongoing strategic partnering efforts
    • Lead principal investigator, Dr. Voskuhl, to report detailed study results (2H-2014)"

    So the real facts are per study protocol, investigators anticipated a 29% decrease in relapse rate at both 12 and 24 months while SYN achieved 47% and 32% respectively !!!

    Trimesta is a success based on the the initial protocol and it's the reason we can call these results as VERY POSITIVE.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Looks Runnerish!!!

    by fanelli_robert Jun 30, 2014 11:38 AM
    galaberge galaberge Jul 1, 2014 1:40 PM Flag

    BUMP BUMP

    Sentiment: Strong Buy

  • galaberge by galaberge Jul 1, 2014 12:34 PM Flag

    I hate these gaps when the markets open at 09:30. Not all the gaps should be closed (breakaway gap don't need to be closed for example) but most of them have to be closed.

    Long and strong SYN

    Sentiment: Strong Buy

  • Company Expects to Initiate C. difficile Clinical Trials in 2014

    I quote :

    "The new Clinical Advisory Board (CAB) is comprised of industry leaders Mark Wilcox, M.D., (Chairman), Curtis Donskey, M.D., Ciarán Kelly, M.D. and Tom Louie, M.D., all of whom will provide expertise and guidance on each aspect of the C. diff clinical program.

    Professor Mark Wilcox M.D., FRCPath, is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK.
    Curtis Donskey, M.D., is Associate Professor of Medicine at Case Western Reserve University School of Medicine, as well as Chairman of the Infection Control Committee at the Louis Stokes Cleveland Veterans' Affairs Medical Center.
    Ciarán P. Kelly, M.D., is Professor of medicine at Harvard Medical School, as well as Director of Gastroenterology Fellowship Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center in Boston, MA.
    Thomas Louie, M.D., is Professor of Medicine in the department of medicine and microbiology-immunology & infectious diseases at the University of Calgary in Alberta, Canada.

    "As we move closer to initiating human clinical trials of SYN-004, and build our global leadership position in the C. difficile prevention space, we are pleased to assemble this group of highly experienced and knowledgeable advisors to guide clinical development of our program," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics.

    Synthetic Biologics expects to initiate Phase Ia and Ib clinical trials to evaluate SYN-004 in the second half of 2014, with preliminary topline data expected by year-end 2014. A Phase II efficacy study of SYN-004 is expected to begin in the first half of 2015."

    Great news

    Long and strong SYN

    Sentiment: Strong Buy

  • Just Google “Clostridium difficile: An intestinal infection on the rise”

    After reading this article everybody will understand why SYN-004 will become the SOC (Standard Of Care) in preventing C-Diff, when approved.

    The C-Diff is due to the antibiotics! As they say in this article “C. diff is an old bacterium, but the CDAD epidemic is relatively new. What turned a medical curiosity into a major threat? In a word, antibiotics.”

    But we can’t suppress the antibiotics as they are vital for numerous other infections.

    The solution:

    So the SOC will be in the near future for the physicians to prescribe SYN-004 simultaneously (it’s the key word “simultaneously”) with antibiotics to counteract the bad effects of antibiotics on the microbiome present in the intestine of the human beings.

    SYN-004 will fulfill an unmet and vital need for tens of millions of people.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Bulls and Bears

    by mdr0418 Jun 27, 2014 10:13 AM
    galaberge galaberge Jun 27, 2014 11:39 AM Flag

    mdr0418- I fully agree with what you say. A YMB is intended to share our ideas to make money and not to make a propaganda of nonsense. People want to know something true when reading our posts. So we have to act accordingly.

    Have a good day.

    Sentiment: Strong Buy

  • If not.....he or she is a clown and a person with selfish motives to mislead and steal other people's money. Not honorable at all.

    Sentiment: Strong Buy

  • To help understanding a fecal tranplant go to the website "womensmedicineDOTorg/frequently-asked-questions-about-fecal-transplantationDOThtml"

    All physicians have a reluctance to do a Fecal Transplant for obvious reasons ...even if it works when properly applied in a hospital !!

    SYN-004 and fecal transplant are 2 different things for 2 different problem. We can't oppose PREVENTION (SYN-004) to a POSSIBLE CURE (fecal transplant).

    Long and strong SYN

    Sentiment: Strong Buy

  • I quote :

    "Synthetic Biologics, Inc. (NYSE MKT: SYN), today announced that researchers at Cedars-Sinai Medical Center (Cedars-Sinai) found that eradication of breath methane and reduction of intestinal levels of the most common methanogenic bacterium in the human gut (M. smithii) resulted in improved insulin sensitivity by up to 50 percent, and a reduction in total cholesterol and LDL cholesterol levels in pre-diabetic, obese human subjects."

    Good news again for the those suffering of this health problem....and for the longs.

    Long and strong SYN

    Sentiment: Strong Buy

  • Just a reminder for all longs :
    "Synthetic Biologics Inc. (SYN) announced that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. SYN's extensive C. diff patent estate now includes over 25 U.S. and international patents.

    The recent European patents EP1451292 and EP2038411 were validated in 16 major European nations and provide composition of matter coverage for strains that allow production of SYN's proprietary oral enzymes and potential further candidate oral enzymes, respectively. In addition, allowed Australian Patent Application 2011257092 contains claims to compositions and methods of using the SYN's lead C. diff candidate, SYN-004.

    C. diff infections are a leading cause of hospital acquired infections that generally occur secondary to treatment with IV antibiotics, which are administered to approximately 14.4 million patients in the United States annually.

    SYN is in preclinical development of SYN-004, a novel second generation oral enzyme drug candidate, for co-administration with commonly used intravenous (IV) antibiotics intended to protect the gastrointestinal microflora (microbiome) from the effects of IV antibiotics for the prevention of C. diff infections."

    Long and strong SYN

    SYN is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases.

    Sentiment: Strong Buy

  • Reply to

    Follow the smart money !!

    by mdr0418 Jun 20, 2014 11:52 AM
    galaberge galaberge Jun 20, 2014 12:31 PM Flag

    MDR0418-Good morning. I see you have not lost your amazing ability to find credible and truthful information. It reminds me of when we were on the same YMB of Questcor. We will have the same success with SYN we had with QCOR. In my mind you're one of the best man to post acurate info. Thanks and I will do my best to compete you on finding very precise info.

    Have a great day.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    1.82 !! Buckle up!!!

    by mdr0418 Jun 19, 2014 9:42 AM
    galaberge galaberge Jun 20, 2014 9:31 AM Flag

    Bump

    Sentiment: Strong Buy

  • Reply to

    So much anger

    by y0da7119 Jun 19, 2014 3:49 AM
    galaberge galaberge Jun 20, 2014 9:27 AM Flag

    Hey id..t ! Trimasta wasn't a failure. It was a great test and we have found incredible data with this test. Stop yelling on this board and sell your shares. I will buy all of them little baby.

    You're a real nuisance poor b.a$t..d

    Strong SYN

    Sentiment: Strong Buy

QCOR
92.96-0.53(-0.57%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
MGIC Investment Corp.
NYSEFri, Jul 11, 2014 4:01 PM EDT